CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead
oleh: Eldad Zacksenhaus, Jeff C. Liu, Letizia Granieri, Ioulia Vorobieva, Dong-Yu Wang, Ronak Ghanbari-Azarnier, Huiqin Li, Amjad Ali, Philip E.D. Chung, YoungJun Ju, Zhe Jiang, Mariusz Shrestha
| Format: | Article |
|---|---|
| Diterbitkan: | Taylor & Francis Group 2018-07-01 |
Deskripsi
The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic.